Stocklytics Platform
Asset logo for symbol UTHR
United Therapeutics
UTHR73
$374.02arrow_drop_up0.06%$0.24
High Quality
Asset logo for symbol UTHR
UTHR73

$374.02

arrow_drop_up0.06%
Key Stats
Open$375.78
Prev. Close$373.97
EPS22.78
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
LOWHIGH
Day Range368.78
378.88
52 Week Range208.62
378.88
Ratios
EPS22.78
Fundamentals
Payout Ratio-
Industry average yield2.94%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

UTHR-
US Healthcare Sector-
US Market-
warning

UTHR / Market

UTHR lose to the US Market which returned 0.39% over the last twenty four hours.
warning

UTHR / Healthcare Sector

UTHR lose to the US Healthcare sector which returned 3.96% over the last twenty four hours.

United Therapeutics (UTHR) Statistics

United Therapeutics Corp (UTHR) is a pharmaceutical company that focuses on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. The company is known for its expertise in the field of pulmonary arterial hypertension (PAH) and is dedicated to improving the lives of these patients through the discovery and development of groundbreaking therapies.
When it comes to UTHR's stock statistics, there are several important metrics to consider. One of these is the valuation metrics, which help investors determine whether a stock is overvalued or undervalued. UTHR has a price-to-earnings ratio of 28.39, indicating that the stock may be slightly overvalued. Additionally, the company has a price-to-sales ratio of 3.37, which suggests that UTHR's stock may also be undervalued relative to its peer group. These metrics provide insight into the company's current valuation and can help investors make more informed decisions about whether to buy or sell UTHR's stock.
add United Therapeutics to watchlist

Keep an eye on United Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has United Therapeutics (UTHR) stock's performance compared to its sector and the market over the past year?

Over the past year, United Therapeutics (UTHR) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 31.06%, United Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 72.87%, it has fallen short of the market average. This comparison highlights United Therapeutics's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of United Therapeutics (UTHR) stock?

The PE (Price to Earnings) ratio of United Therapeutics (UTHR) is currently 16.42. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.
help

What is the EPS of United Therapeutics (UTHR) stock?

The Earnings Per Share (EPS) for United Therapeutics (UTHR), calculated on a diluted basis, is $22.78. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of United Therapeutics (UTHR) stock?

The operating margin for United Therapeutics (UTHR) is 54.51%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of United Therapeutics (UTHR) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of United Therapeutics (UTHR) is $1.62B. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does United Therapeutics (UTHR) have?

United Therapeutics (UTHR) has a total debt of $400M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$1.15B.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level